BioRestorative Therapies/$BRTX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About BioRestorative Therapies
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Ticker
$BRTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
11
ISIN
US0906556065
Website
BRTX Metrics
BasicAdvanced
$12M
-
-$1.48
77.51
-
Price and volume
Market cap
$12M
Beta
77.51
52-week high
$2.28
52-week low
$1.35
Average daily volume
180K
Financial strength
Current ratio
2.237
Quick ratio
2.185
Profitability
EBITDA (TTM)
-12.055
Gross margin (TTM)
92.08%
Net profit margin (TTM)
-3,093.59%
Operating margin (TTM)
-3,133.89%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-54.16%
Return on equity (TTM)
-117.16%
Valuation
Price to revenue (TTM)
32.449
Price to book
1.9
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
-1.436
Free cash flow yield (TTM)
-69.63%
Free cash flow per share (TTM)
-107.92%
Growth
Revenue change (TTM)
161.54%
Earnings per share change (TTM)
33.95%
3-year revenue growth (CAGR)
107.13%
10-year revenue growth (CAGR)
-4.20%
3-year earnings per share growth (CAGR)
-56.33%
BRTX News
AllArticlesVideos
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
GlobeNewsWire·3 weeks ago
BioRestorative Announces Share Repurchase Program
GlobeNewsWire·3 weeks ago
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioRestorative Therapies stock?
BioRestorative Therapies (BRTX) has a market cap of $12M as of July 06, 2025.
What is the P/E ratio for BioRestorative Therapies stock?
The price to earnings (P/E) ratio for BioRestorative Therapies (BRTX) stock is 0 as of July 06, 2025.
Does BioRestorative Therapies stock pay dividends?
No, BioRestorative Therapies (BRTX) stock does not pay dividends to its shareholders as of July 06, 2025.
When is the next BioRestorative Therapies dividend payment date?
BioRestorative Therapies (BRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioRestorative Therapies?
BioRestorative Therapies (BRTX) has a beta rating of 77.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.